Application for clinical acceptance of kabalatin heavy tartrate tablets, a new Alzheimer's drug of Jingxin Pharmaceutical Co., Ltd

According to the information on the website of the State Food and Drug Administration (CFDA), the application of kabalatin tartrate tablets from Beijing New Pharmaceutical Co., Ltd has been accepted clinically At present, there is no domestic enterprise to approve kabalastine bitartrate tablets, and only one original research and production of capsule According to the public information, carbalatin bitartrate is an acetylcholinesterase inhibitor, which is the mainstream drug for the treatment of Alzheimer's disease The original manufacturer is Novartis The experimental data showed that kabalatin tartrate was well tolerated to mild and moderate Alzheimer's disease due to no metabolism of liver and P450 (cytochrome) It was highly evaluated in a prospective, randomized, multicenter, double-blind study conducted in 45 countries including Europe and the United States According to information on CFDA website, at present, the domestic market of kabalanine bitartrate is monopolized by Novartis In 2008, the amount of drug use in sample hospitals was 4.4 million yuan, up 54% year on year It is worth mentioning that in addition to tablets, Beijing New Pharmaceutical Co., Ltd has applied for the production approval of the drug capsule in 2013, and the domestic enterprises that are developing the product include Huahai Pharmaceutical Co., Ltd and Enhua Pharmaceutical Co., Ltd Beijing New Pharmaceutical Co., Ltd is mainly engaged in fluoroquinolones and preparations for cardiovascular, cerebrovascular and digestive systems, and has completed the transformation from APIs to preparations However, at present, the company's preparation products are relatively single, and the market is optimistic that the company's reserve varieties will successively launch a rich product line.